U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
TREMELIMUMAB
QEN1X95CIX
US Approved Rx (2022)
First approved in 2022
General
Record Details
Variant Concepts
1
Names
13
Classification
4
Identifiers
11
Subunits
4
Disulfide Links
16
Glycosylation
2
Relationships
2
Active Moiety
1
Characteristic Attributes
2
TREMELIMUMAB
QEN1X95CIX
US Approved Rx (2022)
First approved in 2022
General
Approval Year
2022
358
Record Details
Substance Class
Protein
Protein Type
MONOCLONAL ANTIBODY
Protein Sub Type
IGG2
Sequence Origin
HUMAN
Sequence Type
COMPLETE
Record UNII
QEN1X95CIX
Record Status
Validated (UNII)
Record Version
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Show
5
20
100
All
entries
Related Record
Type
Related Record
Type
No data available in table
Showing 0 to 0 of 0 entries
Previous
Next
Names
13
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
TREMELIMUMAB
Official Name
English
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Common Name
English
CP-675206
Code
English
TREMELIMUMAB [JAN]
Common Name
English
TREMELIMUMAB (GENETICAL RECOMBINATION) [JAN]
Common Name
English
Showing 1 to 5 of 13 entries
Previous
1
2
3
Next
Classification
4
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of hepatocellular carcinoma
FDA ORPHAN DRUG
721419
Designated/Withdrawn
ORPHAN DRUG
Designated/Withdrawn
Treatment of stage IIb to stage IV metastatic melanoma
FDA ORPHAN DRUG
227306
Monoclonal Antibody
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Monoclonal Antibody
[C20401]
Anti-CTLA-4 Monoclonal Antibody
NCI_THESAURUS
C128036
Designated/Withdrawn
ORPHAN DRUG
Designated/Withdrawn
Treatment of malignant mesothelioma
FDA ORPHAN DRUG
466014
Showing 1 to 4 of 4 entries
Previous
1
Next
Identifiers
11
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
USAN
RR-51
PRIMARY
DRUG BANK
DB11771
PRIMARY
NCI_THESAURUS
C49085
PRIMARY
FDA UNII
QEN1X95CIX
PRIMARY
CAS
745013-59-6
PRIMARY
Showing 1 to 5 of 11 entries
Previous
1
2
3
Next
Subunits
4
Disulfide Links
16
Show
5
20
100
All
entries
From
To
From
To
1_22
1_96
1_139
3_214
1_152
1_208
1_227
2_227
1_228
2_228
Showing 1 to 5 of 16 entries
Previous
1
2
3
4
Next
Glycosylation
2
Glycosylation Type
MAMMALIAN
Show
5
20
100
All
entries
Glycosylation Link Type
Site
Glycosylation Link Type
Site
N
1_301
N
2_301
Showing 1 to 2 of 2 entries
Previous
1
Next
Relationships
2
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
KYU4T5WAI2
CYTOTOXIC T-LYMPHOCYTE PROTEIN 4
TARGET -> INHIBITOR
Tremelimumab-ACTL
SUB_CONCEPT->SUBSTANCE
Amount:
Showing 1 to 2 of 2 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
QEN1X95CIX
TREMELIMUMAB
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Characteristic Attributes
2
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Molecular Formula
CHEMICAL
ESTIMATED
C6500H9960N1726O2026S52
MOL_WEIGHT:SEQUENCE
CHEMICAL
SEQUENCE 146353.48 Da (average)
Showing 1 to 2 of 2 entries
Previous
1
Next
